Search results for "Highlights"


 
Results 11 - 20 of about 38 for "Highlights".

ACIP revises recommendations on hepatitis A vaccination

For postexposure prophylaxis, the hepatitis A vaccine is now preferred to immune globulin for all adults, including those older than 40 years of age, the Advisory Committee on Immunization Practices (ACIP) said.
November 2018

GI safety profile varies among direct oral anticoagulants

Three propensity-matched cohorts of patients with nonvalvular atrial fibrillation who had incident exposure to dabigatran, rivaroxaban, or apixaban were compared.
January 2017

Patients may not always want to stop low-value colorectal cancer screening

Veterans at one health system were asked to rate the reasonableness of using age and risk calculators in decisions about screening cessation.
December 2018

Introducing ACP Gastroenterology Monthly

Welcome to the first issue of ACP Gastroenterology Monthly, a new free monthly e-newsletter from the American College of Physicians, designed to inform primary care physicians of the current literature in gastroenterology/hepatology.
January 2017

Efficacy, safety of second-line therapies analyzed for two types of IBS

A systematic review and network meta-analysis focused on alosetron, eluxadoline, ramosetron, and rifaximin in adult patients who had irritable bowel syndrome (IBS) with diarrhea or mixed stool.
April 2019

Beta-blockers linked to better outcomes in some patients with cirrhosis

Decompensation-free survival improved in patients with cirrhosis and portal hypertension who received beta-blockers versus placebo, largely due to a decrease in ascites.
April 2019

Statins associated with lower risk for postcolonoscopy colorectal cancer

The primary outcome of the retrospective cohort study was postcolonoscopy colorectal cancer within three years, defined as colorectal cancer diagnosed within six and 36 months after negative findings on index colonoscopy.
March 2019

Combination therapy for IBD carries higher infection risk than monotherapy

Monotherapy for inflammatory bowel disease (IBD) with an immunosuppressive agent was associated with a lower risk of serious infection than a tumor necrosis factor (TNF) antagonist alone or an anti-TNF plus an immunosuppressive agent, according to a
March 2019

Halting one ulcerative colitis treatment after escalating to new drug may be feasible, study finds

Patients with ulcerative colitis treated with 5-aminosalicylates who require escalation to anti-tumor necrosis factor-alpha (anti-TNF) therapy may be able to safely discontinue the first drug.
November 2018

Guideline recommends standardized management of mild to moderate ulcerative colitis

The guideline focuses on oral and topical 5-aminosalicylic acid medications, rectal corticosteroids, and oral budesonide in patients with mild to moderate disease.
December 2018

Result Page: Prev   1   2   3   4   Next